Ni-catalyzed enantio- stereoselective synthesis of chiral chromans with quaternary allylic siloxanes and their antitumor activity

30 May 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Nickel-catalyzed efficient asymmetric synthesis of chiral chromans with quaternary allylic siloxanes and their antitumor activity is reported for the first time. A P-chiral monophosphine ligand (R)-AntPhos was found to be the ideal ligand to form a series of tertiary allylic siloxanes bearing chroman structures with excellent yields, enantioselectivities and E/Z selectivity using triethylsilane as the reductant. This reaction has a broad substrate scope and provides a practical way to synthesize useful chroman derivatives with chiral tertiary allylic alcohols. Up to 69 examples were successfully established with this method. A series of 3-hydroxychroman derivatives were obtained and tested for anti-tumor activity. Number of compounds showed good anti-tumor activity, less toxicity to reference cell, and specificity to different cancer cells, which could be new anticancer leading compounds. The configuration and substituent of the 3-hydroxychromans has big effects for their anti-tumor activity. Further study on structure-activity relationships of these 3-hydroxychromans is under investigation to discover new anti-cancer drugs.

Keywords

Ni-catalyzed Reductive Cyclization
Asymmetric Catalytic Synthesis
Chiral Chromans with Quaternary Allylic Siloxanes
Antitumor Activity
3-Hydroxychromans

Supplementary materials

Title
Description
Actions
Title
SUPPORTING INFORMATION for the content
Description
Methods and procedures, HPLC, NMR
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.